Clinical utility of clonal origin determination in managing recurrent hepatocellular carcinoma. (3rd October 2021)

• Record Type: Journal Article
• Authors: Gupta, Shubham; Khan, Sikandar; Kawka, Michal; Gujjuri, Rohan; Chau, Ian; Starling, Naureen; Cunningham, David; Jiao, Long R; Gall, Tamara
• Is Part Of: Expert review of gastroenterology & hepatology. Volume 15:Number 10(2021)
• Page Start: 1159
• Page End: 1167
• Publication Date: 2021-10-03
• Subjects: Clonal origin -- hepatocellular carcinoma -- molecular techniques -- outcomes -- recurrence -- survival; Gastroenterology -- Periodicals; Liver -- Diseases -- Periodicals; 616.3
• DOI: 10.1080/17474124.2021.1967144
• Languages: English
• ISSNs: 1747-4124

Abstract

ABSTRACT: Introduction: Recurrence is the driving factor for reduced long-term survival in patients following resected hepatocellular carcinoma (HCC). Extensive research efforts have been conducted to understand the molecular processes precipitating disease recurrence. Modern genomic techniques have identified two distinct mechanisms for recurrent HCC (RHCC): Intrahepatic metastasis (IM-HCC); and multicentric origin (MO-HCC). Medline, EMBASE and Cochrane library were methodically searched for primary research articles in English with the aim of appraising existing literature on the identification of clonal origin of RHCC and its potential clinical utility. Areas covered: Molecular and next-generation sequencing techniques, when applied to clonal origin identification, yield superior accuracy than traditional clinicopathological criteria. Despite various treatment modalities, no optimal therapy has yet been identified for treating clonally differentiated RHCC. Patients with MO-HCC appear to experience improved long-term survival following re-treatment compared to their IM-HCC counterparts (91.7% vs 22.9% 5-year survival, p < 0.001). However, cautious interpretation is advised as heterogeneous classification criteria and small sample sizes restrict the generalizability of such findings. Expert opinion: Improved identification of clonal origin in RHCC may facilitate further research on RHCC treatment strategies and enable the development of novel therapeutic targets, potentially leading to individualized treatment approaches in the future.